| Document |
Document Title |
|
WO/2021/059058A1 |
A self-contained biological sterilization indicator comprises: a housing; bacterial spores comprising, and/or capable of producing, an enzyme capable of catalyzing cleavage of an enzyme substrate; and a frangible container containing a c...
|
|
WO/2021/037077A1 |
Patentiflorin A analogs that are useful as antivirals, such as anti-HIV, anti-coronaviral, anti-Ebola viral, and anti-influenza viral agents and methods of use thereof.
|
|
WO/2021/031594A1 |
Disclosed are a novel aromatic ring compound represented by general formula (I), an isomer, a prodrug, a solvate, a pharmaceutically acceptable salt and a pharmaceutical composition thereof, and use thereof for preparing medicaments for ...
|
|
WO/2021/030183A1 |
Disclosed are compositions comprising a polyene macrolide antibiotic and an azole antifungal, and packaged pharmaceutical products comprising the disclosed compositions. Also disclosed are methods of treating systemic fungal infections c...
|
|
WO/2021/022690A1 |
The present invention relates to the field of chemical synthesis, in relates particular to a nucleoside salt represented by formula (III) or formula (IV), and a preparation method therefor. The method provided by the present invention is...
|
|
WO/2021/025444A1 |
Despite various functions discovered of polyphenol-based compounds in regulating biological responses, such compounds, due to difficulty in procuring same in sufficient amounts with a high enough purity to permit application in pharmaceu...
|
|
WO/2021/026450A1 |
Disclosed are C16 ester derivatives of C2'epi-amphotericin B (C2'epiAmB) characterized by improved clinical efficacy with reduced toxicity compared to AmB. Also disclosed are pharmaceutical compositions comprising the C 16 ester derivati...
|
|
WO/2021/013155A1 |
Disclosed are a new glycosyl donor, a preparation method therefor, and an application thereof. Specifically, a glycosyl donor represented by formula (I), a preparation method therefor, and a use of the glycosyl donor represented by formu...
|
|
WO/2021/008549A1 |
The present invention belongs to the field of pharmaceutical chemistry. Specifically, the present invention relates to a novel compound and a pharmaceutical composition. The novel compound has a structural formula represented by formula ...
|
|
WO/2020/255865A1 |
[Problem] The objective of the present invention is to provide topical composition having a much higher whitening effect. [Solution] This topical composition, characterized by comprising (A) ascorbic acid and/or a derivative thereof, (B)...
|
|
WO/2020/251862A1 |
The present invention provides methods and kits to improve the signal from sialic acids labeled with the dye 1, 2-diamino-4, 5-methylenedioxybenzene ("DMB"). The methods include labeling the sialic acids with DMB in an aqueous solution c...
|
|
WO/2020/244148A1 |
The present application relates to a doramectin polymorph. Specifically, the present application relates to doramectin crystal form A, crystal form B, and a preparation method thereof. The polymorph can be obtained by dissolving doramect...
|
|
WO/2020/244253A1 |
Disclosed is an application of a small molecule compound or a pharmaceutically acceptable salt thereof in the preparation of an anti-tumor metastasis drug. The structure of the compound is as shown in formula (I). The small molecule comp...
|
|
WO/2020/241759A1 |
[Problem] To provide a novel medicine for preventing and/or treating influenza virus infection or corona virus infection. [Solution] According to the present invention, provided are an anti-influenza virus agent, an anti-corona virus age...
|
|
WO/2020/238528A1 |
The invention relates to an intermediate TSL-1502M of a PARP inhibitor and a preparation method thereof. The structural formula of the intermediate is as shown. The preparation method includes the following step: under the action of sodi...
|
|
WO/2020/212760A2 |
Described herein are compositions and methods for the treatment of ocular surface disorders including meibomian gland dysfunction, blepharitis, dry eye disease and other inflammatory/ infections disease of the anterior surface of the eye...
|
|
WO/2020/198883A1 |
Transdermal medicaments containing cannabidiol (CBD) for use in the amelioration of conditions, including anxiety, depression, pain, inflammation, epilepsy, parkinson's disease, oxidative injury and nausea; and a method for preparing same.
|
|
WO/2020/198578A1 |
The disclosure relates to methods of forming a dihydrochalcone using electrocatalytic dehydrogenation. In particular, the disclosure relates to methods of forming a dihydrochalcone electrocatalytically hydrogenating (ECH) a reactant comp...
|
|
WO/2020/194237A1 |
Methods of rapidly inhibiting efflux from a cell, sensitizing a drug-resistant cell to a drug and treating a subject with a drug-resistant pathology, by administering tetrahydrocannabinolic acid (THCa), cannabidiol (CBD) or a combination...
|
|
WO/2020/170840A1 |
The present invention addresses the problem of providing a novel crystal of 2-O-α-D-glucosyl-L-ascorbic acid and a method for producing the crystal. The problem is solved by providing a crystal of the potassium salt of 2-O-α-D-glucosyl...
|
|
WO/2020/160443A1 |
Methods for preparing a polyene macrolide antifungal with improved aqueous solubility. The method involves providing a polyene macrolide antifungal having a carboxylic acid group; activating the carboxylic acid group; introducing a prima...
|
|
WO/2020/132480A1 |
Compositions for treating an autoimmune, inflammatory, fibrotic, or proliferative disease or disorder comprising a compound that inhibits hyaluronan synthesis and a pharmaceutically acceptable carrier are described. In some embodiments, ...
|
|
WO/2020/127843A1 |
The present disclosure relates to a compound of Formula (I): or anyone of its metabolites or a pharmaceutically acceptable salt thereof, for use for treating and/or preventing an inflammatory disease, disorder or condition, wherein each ...
|
|
WO/2020/119773A1 |
The present disclosure relates to the field of medicine, and specifically relates to an amphotericin B peptide derivative and a preparation method therefor. The amphotericin B peptide derivative has a broad-spectrum and highly effective ...
|
|
WO/2020/115661A1 |
A self-contained biological sterilization indicator comprises: a housing; bacterial spores comprising, and/or capable of producing, an enzyme capable of catalyzing cleavage of an enzyme substrate; and a frangible container containing a c...
|
|
WO/2020/104697A1 |
The present invention relates to a synthetic saccharide of general formula (I) that is related to Clostridium difficile PS-II cell-surface polysaccharide and conjugate thereof. Said synthetic saccharide, said conjugate and pharmaceutical...
|
|
WO/2020/106636A1 |
Provided are 13-membered macrolides for the treatment of infectious diseases. The 13- membered macrolides described herein are azaketolides. Also provided are methods for preparing the 13-membered macrolides, pharmaceutical compositions ...
|
|
WO/2020/106780A1 |
Provided herein are compounds or payloads, linker-payloads, antibody-drug conjugates, and compositions, and methods for the treatment of diseases and disorders associated with the liver X receptor, including bis-octahydrophenanthrene car...
|
|
WO/2020/106627A1 |
Provided are 13-membered macrolides for the treatment of infectious diseases. The 13-membered macrolides described herein are azaketolides. Also provided are methods for preparing the 13- membered macrolides, pharmaceutical compositions ...
|
|
WO/2020/079224A1 |
This invention relates to compounds that are useful as cancer therapies. The compounds comprise azithromycin derivatives having a phosphonium cation tethered to the azithromycin macrocycle. The invention also relates to methods of using ...
|
|
WO/2020/057546A1 |
A cyclic dinucleotide analogue, a pharmaceutical composition thereof, and application. A cyclic dinucleotide analogue (I), an isomer thereof, a prodrug, a stable isotope derivative, or a pharmaceutically acceptable salt has the following...
|
|
WO/2020/048049A1 |
Disclosed are a method for preparing a Luo Han Guo sweetner composition from Siraitia grosvenorii and a use thereof. The method for extracting the sweetener composition from Siraitia grosvenorii preferably comprises the following steps: ...
|
|
WO/2020/050663A1 |
The present invention relates to a method for chemical production of 3,6-anhydro-L-galactitol (L-AHGol), which is a novel sugar alcohol, and agarobititol (ABol), which is a disaccharide having the same agarobititol as a reductant end the...
|
|
WO/2020/051465A1 |
Disclosed are derivatives of amphotericin B (AmB) characterized by improved clinical efficacy with reduced toxicity compared to AmB. Also disclosed are pharmaceutical compositions comprising the AmB derivatives, therapeutic methods of us...
|
|
WO/2020/038279A1 |
A substituted pyrazole compound represented by formula I, and a preparation method, a pharmaceutical composition, and use thereof. The compound has good stability, excellent solubility, small cell toxicity, and a significant effect on ne...
|
|
WO/2020/040233A1 |
The present invention provides a method for obtaining a specifically-shaped crystal (specifically, spherocrystal) of a compound with good reproducibility. This method for producing a specifically-shaped crystal (specifically spherocrysta...
|
|
WO/2020/035553A1 |
The present invention is directed to a process for purifying natamycin, to an epoxide polyene amphoteric macrolide, to a composition comprising said polyene amphoteric macrolide and to a process for preparing said polyene amphoteric macr...
|
|
WO/2020/035552A1 |
The present invention is directed to a process for purifying natamycin, to an all-trans polyene amphoteric macrolide, to a composition comprising said polyene amphoteric macrolide and to a process for preparing said polyene amphoteric ma...
|
|
WO/2020/032752A1 |
The present invention relates to a catechin compound or a pharmaceutically acceptable salt thereof, and a use thereof, and a catechin compound or a pharmaceutically acceptable salt thereof of the present invention is very effective in th...
|
|
WO/2020/032744A1 |
The present invention relates to a catechin compound or a pharmaceutically acceptable salt thereof, and a use thereof, and a catechin compound or a pharmaceutically acceptable salt thereof of the present invention is very effective in th...
|
|
WO/2020/029168A1 |
A natamycin superfine powder, a preparation method therefor and the use thereof. The natamycin superfine powder is a solid powder, and has no fixed shape under a transmission electron microscope, and no less than 95% of the shape size is...
|
|
WO/2020/021574A1 |
Pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof: Formula (I) for modulating one or more cytokines such as: Tumor necrosis factor-α (TNF-α), Interleukin-1 (IL-1), Interleuki...
|
|
WO/2020/005111A1 |
The invention relates to chemistry and pharmacology, specifically to polymer complexes of a macrolide antibiotic. The claimed substance is a product of the interaction of a macrolide antibiotic with a copolymer of acrylamide and 2-acryla...
|
|
WO/2019/241895A1 |
Provided are transgenic organisms, such as plants and plant parts, cells, and related compositions and methods for producing and monitoring the genotype for enhanced production of montbretin A and/or its precursors. For example, provided...
|
|
WO/2019/241947A1 |
Disclosed is a method of separating and purifying icariin from Epimedium extract, relating to the technical field of separating and purifying a single component from a plant extract, and is intended to address the issues of complicated p...
|
|
WO/2019/241461A1 |
The present disclosure relates to compounds of Formula (1), which inhibit Gal-3, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods making and using such compounds and compositions.
|
|
WO/2019/228260A1 |
The present invention relates to a crystal form I of tenvermectin B. The crystal form I of tenvermectin B can be represented by means of an X-ray powder diffraction (XRPD) spectrum, an infrared (IR) absorption spectrum, a differential sc...
|
|
WO/2019/191352A9 |
Disclosed herein are methods, sodium-dependent glucose transporter (SGLT)1 compounds and compositions for the treatment of postprandial hypoglycemia, postprandial hypoglycemia that occurs as a consequence of gastric surgery.
|
|
WO/2019/201268A1 |
Disclosed are a drug used for preventing and/or treating pain and/or fever, a combination product, and a use thereof; the active ingredient of said drug comprises one of carrimycin, isovaleryl spiramycin III, isovaleryl spiramycin II, an...
|
|
WO/2019/191830A1 |
The present application relates generally to the treatment of integumentary wounds (including chronic and acute wounds involving both cutaneous and mucous membranes), and in particular to topical formulations and instillates comprising o...
|
